‘Remarkable’ Cancer Treatment Study Shows Stunning Results: ‘The First Time This Has Happened’

AHA Publisher — Wed, 08 Jun 2022 07:00:32 +0000

Tré Goins-Phillips, Faithwire via CBN News – A gastrointestinal medical oncologist is praising a “promising” cancer treatment study, calling the new data “very encouraging” after every participant walked away from the trial cancer-free. Dr. Hanna K. Sanoff of the UNC Lineberger Comprehensive Cancer Center called the monoclonal antibody used to treat the patients, dostarlimab, “remarkable,” but nevertheless encouraged cautious optimism “until the results can be replicated in a larger and more diverse population.”The impressive data are the result of a small cancer treatment trial led by doctors at Memorial Sloan Kettering Cancer Center in New York City and backed by the pharmaceutical company GlaxoSmithKline. The results of the 18-person trial were first outlined Sunday in the New England Journal of Medicine. From the study: We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. As The Times described it, the antibody treatment “unmasks cancer cells, allowing the immune system to identify and destroy them.” After completing the regimen, none of the trial participants had to seek further cancer treatment because they all had “a clinical complete response, with no evidence of tumor on magnetic resonance imaging,” according to the authors of the study. “At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months),” the doctors explained. “No adverse events of grade 3 or higher have been reported.” One of the authors of the peer-reviewed paper, Dr. Luis A. Diaz, Jr., told The New York Times, “I believe this is the first time this has happened in the history of cancer.” While it’s not yet clear whether the patients truly are “cancer-free,” the findings are certainly encouraging, given most rectal cancer patients undergo chemotherapy, radiation, and often life-altering surgeries that bring with them serious lifestyle changes. Knowing that is typically the case, it’s an understatement to say each of the patients in the trial were surprised to learn no further treatment was necessary, at least at this point. Dr. Alan P. Venook, a colorectal cancer specialist at the University of California, San Francisco, told The Times it is “unheard of” for every patient in a study, all of whom had rectal cancer, to leave in remission. He was also struck by the absence of side effects from the dostarlimab, also known as a checkpoint inhibitor, noting that 3-5% of patients typically have severe complications. Most side effects, it should be noted, are managed easily. Venook said lack of side effects experienced by participants shows “either they did not treat enough patients or, somehow, these cancers are just plain different.” An oncologist at Memorial Sloan Kettering Cancer Center, Dr. Andrea Cercek, one of the study’s authors, recounted “a lot of happy tears” when the study’s stunning results were shared with the cancer patients. Dr. Kimmie Ng, a colorectal cancer expert at Harvard Medical School, echoed Sanoff’s cautious optimism, urging further research but commending the just-released data as “remarkable” and “unprecedented.” Sarnoff, for her part, said the results of the first 12 of a planned 30-person trial are “remarkable and exceed what we would expect with the standard chemotherapy plus radiation.” “Although quality of life measures have not been reported yet,” she added, “it’s encouraging that some of the most difficult symptoms, such as pain and bleeding, all resolved with the use of dostarlimab.” There is a great deal more to learn here, but it is certainly encouraging. Join us as we praise God for modern medical intervention and pray for true healing for these patients. To read the original article click here.

The post ‘Remarkable’ Cancer Treatment Study Shows Stunning Results: ‘The First Time This Has Happened’ appeared first on Amazing Health Advances.

New Therapy Provides Relief in Patients with Chronic Low Back Pain

AHA Publisher — Tue, 23 Jun 2020 07:00:27 +0000

University of Rochester Medical Center via News-Medical Net – A new study has found that tanezumab, a monoclonal antibody that inhibits nerve activity, provides relief in patients with chronic low back pain, one of the leading reasons why people seek medical care and the number one cause of disability worldwide. “This demonstration of efficacy is a major breakthrough in the global search to develop non-opioid treatments for chronic pain,” said John Markman, M.D., director of the Translational Pain Research Program in the University of Rochester Medical Center (URMC) Department of Neurosurgery and lead author of the study which appears in the journal Pain. “There were also improvements in function linked to the reduction in pain severity.” This is the first study that shows long-term relief for chronic low back pain with a single dose of tanezumab delivered under the skin once every two months. The study was conducted in 191 sites across eight countries in North America, Europe, and Asia. Researchers are increasingly finding that certain proteins circulating in the bloodstream heighten the sensitivity of cells in the nervous system to pain. One of these proteins, called nerve growth factor (NGF), may explain why some individuals experience more intense and chronic back pain. Tanezumab is an NGF inhibitor. The patients with chronic low back pain enrolled in this study did not previously have relief with at least three different types of pain medication, including opioids, and were considered “difficult-to-treat.” Patients with symptoms, signs, and x-ray evidence of moderate-to-severe osteoarthritis, a disorder commonly found in older patients with chronic low back pain, were excluded from the study. Tanezumab has not been associated with the often serious adverse side effects seen with opioids or nonsteroidal anti-inflammatory drugs (NSAIDs), which are often used to treat low back pain. However, this class of drugs has been linked to joint problems, which are sometimes serious enough to require joint replacement. Because of this concern, the researchers followed participants for an extended period and determined there was a low rate of serious joint problems requiring joint replacement. “In the future, clinicians may have to weigh the different risks of lumbar fusion surgery, chronic opioid use, or NSAIDs against the unique risks of a rare but rapidly progressive form of joint problem associated with blocking nerve growth factor. I expect that that the tradeoffs between benefit and risk will be different for osteoarthritis than for chronic low back pain.” John Markman, M.D., Director of the Translational Pain Research Program in the University of Rochester Medical Center (URMC) Department of Neurosurgery. To read the original article click here.

The post New Therapy Provides Relief in Patients with Chronic Low Back Pain appeared first on Amazing Health Advances.

monoclonal antibody Archives - Amazing Health Advances

‘Remarkable’ Cancer Treatment Study Shows Stunning Results: ‘The First Time This Has Happened’

New Therapy Provides Relief in Patients with Chronic Low Back Pain